Latest Tax Refunds News

Vectus Biosystems has signed a binding agreement to sell its VB4-P5 renal fibrosis compound to Canadian biotech XORTX Therapeutics, while actively pursuing licensing opportunities for its lead drug VB0004 and others, particularly in China.

Norwood Systems reports a second consecutive quarter of positive operating cash flow, enabling debt reduction and progress in key projects with Optus and Microsoft. The company also secured multiple industry awards, underscoring its innovation momentum.

Patrys Limited has raised $1.77 million through a fully underwritten entitlement offer to fund preclinical studies and business development for its deoxymab therapeutic antibodies. The company also completed a capital consolidation and held a successful AGM, signaling a strategic pivot into immunology and inflammation.

CONNEQT Health reported a $2.6 million operating cash outflow in the September quarter but secured $2 million through a convertible note, while expecting a $1.6 million R&D tax refund to shore up liquidity.

Aurora Labs has advanced its micro gas turbine propulsion program with critical durability testing, a new Defence contract phase, and a strategic $5.5 million capital raise to scale manufacturing and commercialisation.

Sparc Technologies has completed construction of a pioneering green hydrogen pilot plant and secured new patents, while its graphene additive trials show promising corrosion resistance results.

Bioxyne Limited has reported a record quarterly revenue of A$14.1 million for Q1 FY26, driven by strong demand in Europe and Australia, alongside a strategic dual listing on the Frankfurt Stock Exchange.

Cann Group Limited reported a near break-even net operating cash flow for Q1 FY2026 and achieved its first EBITDA-positive month, setting the stage for a major debt restructure that will significantly reduce its borrowings.

Activeport Group Ltd reported steady Q1 FY26 results with key project deliveries and a successful capital raise, positioning the company for accelerated growth across Asia and beyond.

Australian Rare Earths Limited (ASX, AR3) reported strong progress in its Koppamurra Rare Earths Project with high recovery rates and production milestones, while also expanding and resuming drilling at its Overland Uranium Project. The company bolstered its financial position through government grants and option exercises.

Radiopharm Theranostics has secured FDA approval to initiate a Phase I trial targeting B7H3 and raised A$40 million to accelerate its radiopharmaceutical programs. The company also appointed renowned oncologist Dr Oliver Sartor to its Scientific Advisory Board.

Global Health Limited has accelerated its MasterCare+ SaaS platform rollout, integrating AI to streamline operations and reduce staff by 10%, while reporting a 25% EBIT improvement despite a delayed R&D refund impacting cash flow.